Bio-Path (NASDAQ:BPTH) Earns Sell Rating from Analysts at StockNews.com

StockNews.com assumed coverage on shares of Bio-Path (NASDAQ:BPTH) in a research report report published on Tuesday. The brokerage issued a sell rating on the stock.

Bio-Path Stock Down 3.3 %

NASDAQ BPTH opened at $0.17 on Tuesday. The stock has a 50-day moving average of $0.51 and a two-hundred day moving average of $0.80. Bio-Path has a 1-year low of $0.12 and a 1-year high of $7.67.

Bio-Path Company Profile

Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.